Improvement of quality of life in methadone treatment patients in northern Taiwan: a follow-up study by Ying-Chun Chou et al.
Chou et al. BMC Psychiatry 2013, 13:190
http://www.biomedcentral.com/1471-244X/13/190RESEARCH ARTICLE Open AccessImprovement of quality of life in methadone
treatment patients in northern Taiwan:
a follow-up study
Ying-Chun Chou1, Shu-Fang Shih1, Wei-Der Tsai2, Chiang-shan R Li3, Ke Xu3 and Tony Szu-Hsien Lee1*Abstract
Background: This study examined long-term improvement of quality of life amongst heroin users enrolled in
methadone maintenance treatment (MMT).
Methods: The sample contained 553 heroin-dependent individuals from 4 hospitals in northern Taiwan who
enrolled in MMT for an average of 184 days. Each patient signed a consent form and was assessed prospectively 3
times semi-annually. Quality of life was measured using the WHOQOL-BREF questionnaire, 26 items of which were
scored by the participants. The WHOQOL-BREF consists of four domains: physical, psychological, social, and
environmental. 285 and 155 participants completed 6-month and 12-month follow-ups respectively.
Results: After controlling for demographic and clinical characteristics, there were statistically significant
improvements in the psychological and environmental domains between baseline and 6 months. Significant
improvements were found in psychological and social domains between baseline and 12 months.
Conclusions: It is concluded that methadone maintenance treatment improves heroin users’ long-term quality of
life in the psychological and social relationship domains.
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Illicit drug use is a complicated problem that not only
impacts individuals’ physical and psychological health
but also derogates public security and society’s product-
ivity because of morbidity and mortality [1]. It is esti-
mated that about 230 million people, or 5% of the
world’s adult population, used an illicit drug at least
once in 2010 [2]. The report also estimates that heroin,
cocaine, and other drugs kill around 0.2 million people
each year, shattering families and bringing misery to
thousands of other people.
Heroin users are at high risk of morbidity and mortal-
ity. They may struggle with dependence for many years,
suffering poor interpersonal relationships and poor
health [3,4], particularly due to overdosing [5] and hu-
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reproduction in any medium, provided the or(HCV) infections [6,7]. A national study conducted in
Taiwan on 22,224 male and 4,444 female drug offenders
released from prisons without medical treatment shows
that the standardized mortality ratio was seven to one,
much higher than for the general population [8].
Follow-up studies have found that this risk continues
for many years after diagnosis of heroin dependence [9],
indicating that the dependence can be considered
chronic. In fact, heroin addiction is currently defined as
a chronic, relapsing disorder [10,11]. Methadone, a
complete opioid agonist, has been approved as a treat-
ment for heroin addiction, especially with higher doses
[12,13] because it can help patients reduce their fre-
quency of heroin use, alleviate withdrawal symptoms,
and consequently improve overall health and social rela-
tionships [14-16]. Thus, heroin users taking methadone
should be able to improve cognitive functions [17] and
return to normal daily activities. This means that we
would expect quality of life amongst heroin users to im-
prove during treatment [18]. However, according to thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Conditions, fewer than 40% of those diagnosed with
drug dependence in the United States have ever received
any kind of intervention or treatment. In Taiwan, a
methadone maintenance treatment (MMT) program was
initiated to prevent HIV, and the program had expanded
to the entire island by the end of 2006. Currently, about
12,000 out of the 60,000 heroin users in Taiwan partici-
pate in an MMT program everyday [19].
Although opioid treatment programs are effective in
reducing the amount and frequency of heroin use and
its consequences as describe above, prospective research
on possible improvement in quality of life from the pa-
tient’s perspective has been limited. Quality of life was
defined by the WHO as “an individual’s perception of
their position in life, in the context of the culture and
value systems in which they live and in relation to their
goals, expectations, standards and concerns”. Quality of
life has been an important indicator of efficacy in the
treatment of various chronic diseases such as diabetes
and hypertension, creating a transition from cure to
care. In their report of a qualitative interview study,
Laudet, Becker, and White [20] noted that the heroin
users they studied had been suffering considerable nega-
tive consequences from their habit for a very long time.
It is common for heroin users to prefer a return to a
normal life, or just a better life, over the chaotic, abnor-
mal life they had been undergoing. Although published
studies in the addiction field on quality of life remain
sparse, the few that have appeared consistently show
that MMT can improve heroin users’ quality of life
within a short period of time [21-23]. For example,
Maremmani, Oani, Pacini and Perugi [21] studied 213
patients (106 on buprenorphine and 107 on methadone)
between the 3rd and 12th months of treatment for both
medications and found significant improvements in opi-
oid use, psychiatric status, and quality of life. On the
other hand, the authors of a recent review of 38 articles
concluded that the long-term effects of treatment on the
quality of life of heroin using patients remain unclear
[24].
Further, MMT is not free to patients. A recent study
on 2,728 MMT patients in China [25] indicated that per-
ception of suitable MMT cost is a significant predictor
of retention. Moreover, in another study [13] that used a
signal detection analysis on 258 methadone outpatients
to identify predisposing factors that predict treatment
retention, the results showed that satisfaction of treat-
ment is a significant predictor. Additionally, Taiwanese
heroin users have to pay for the medical expenses, which
can be directly related to their satisfaction, participation
and retention in MMT. By comparing the changes of
quality of life at baseline, 6-month and 12-month follow-
up survey, we could evaluate the effectiveness of MMTon quality of life and the monetary costs for per unit
change of quality of life gained. Even though MMT pro-
grams are relatively new in Asia except Hong Kong, we
hypothesized that MMT patients can improve long-term
subjective quality of life of Taiwanese heroin users 6 and
12 months after enrollment in this study. Furthermore,
the ratio of costs over per unit increment of quality of
life may provide a useful index to further evaluate pa-
tient’s perception of suitable costs and treatment satis-
faction and form a basis of policy decision making.
Methods
Study design
We used a 12-month prospective multisite study to
examine the improvement of quality of life from the pa-
tient’s perspective. The study protocol was reviewed and
approved by the institutional review board (IRB) of
Taipei Medical University (approval number: P960205)
and by Taipei City Hospital (approval number: TCHIRB-
970404-E). This was an open, nonrandomized, and ob-
servational study.
Participants
Participants were recruited from four outpatient MMT
clinics in northern Taiwan during the years 2008 and
2009. Each patient at admission self-reported his/her
history of drug use, and underwent morphine, HIV and
HCV tests. Patients paid the associated medical costs of
each MMT service utilized during his/her duration of
treatment, including registration, diagnosis, various tests,
prescription, medication as well as health education,
with the exception of those who were HIV positive. Per
Taiwan’s policy, HIV-positive patients were reimbursed
for all medical costs from Taiwan Department of Health.
Counseling and/or psychotherapy may be offered only
on demand. The inclusion criteria in this study were age
above 20 years, heroin dependence, and literacy. After
signing a consent form, each patient was interviewed
face-to-face by a trained research assistant at three
times: baseline, 6 months into the study, and 12 months
into the study. Each patient was reimbursed approxi-
mately 3 US dollars for each interview.
Quality of life
Based on definition of quality of life, we used the World
Health Organization Quality of Life Assessment-Brief
Version (WHOQOL-BREF), which was developed to
measure overall quality of life and general health status
[26,27]. The WHOQOL-BREF measures four health do-
mains: physical, psychological, social, and environmental.
The WHOQOL-BREF (Taiwanese version) has shown
excellent internal consistency (Cronbach’s alpha = .97)
and good test-retest reliability over 2 weeks for the four
domains (.68 to .85) [27]. The four-domain structure
Table 1 Costs associated with medical services and
examinations in MMTP in 2009 placarded by Taiwan
Department of Health




First-visit diagnostic fees 153.3 153.3
Registration fees 5 75
Prescription fees 10 120
Examination fees
HIV test semiannually 13.3 26.7
Urine test (Morphine) 10 20
Urine test (Amphetamine) 10 20
HBsAg test 8.3 16.7
Anti-HBs test 10 20




SGOT blood test 1.7 3.3
SGPT blood test 1.7 3.3
r-GT test 2.3 4.7
Chest X-ray 10 20
EKG (Electrocardiograph) 0 0
Supportive group education 10 120
Psychotherapy (Family therapy, group
therapy, or other psychotherapies)
106.7 106.7
Healthcare service fees (including
health education and counseling)
0 0
Case management service fees 166.7 166.7
Medication fee (methadone per day) 0.7 243.3
Total 1179.7
Note. Medical payments were collected according to the regulations issued by
the Taiwan Department of Health in 2009 governing payments for prevention,
testing, and treatment of HIV.
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analyses, with factor loadings > 0.40 for the retained
items and CFI > 0.90 [27].
The WHOQOL-BREF questionnaire uses a five-point
Likert scale (1–5). Four types of scale descriptors (cap-
acity, frequency, intensity, and evaluation) were selected
for this study. Participants responded to questions
according to their experience in the previous two weeks.
Reverse items (items 3, 4 and 26) were scored reversely.
Domain scores for the WHOQOL-BREF are calculated
by taking the mean of all items included in each domain
and multiplying by a factor of four. The original domain
scores were transformed to a scale of 0–100 according
to the equation in the published guidelines [26,27]. A
high score represents good quality of life. An increase in
QoL scores after 6- or 12-month treatment would sug-
gest the effectiveness of MMT. Furthermore, given that
each service of MMT has a fixed unit price regulated by
Taiwan Department of Health, the total medical costs of
MMT were computed by summing up the unit prices of
all the services utilized by a patient during his/her 12-
month retention (see Table 1). Medical costs borne by
patients for one QoL score increment can be estimated
by dividing the costs by the changes of QoL scores.
Statistical analysis
Descriptive statistics were used to identify the character-
istics of the entire sample and the two groups of patients
who stayed in or dropped out of MMT during the 6-
month study period. Chi-square and t-test analyses were
performed on categorical and continuous variables re-
spectively to determine if there were significant differ-
ences between the two groups. Quality of life scores,
age, age at first heroin use, education, methadone dose,
and duration in treatment in this study met the normal-
ity assumption. To better estimate the associations
among the four domains of the quality of life between
assessment waves, repeated measures analyses of vari-
ance (ANOVA) with a 0.05 significance level for longitu-
dinal evaluations were performed to examine changes
on the four domains simultaneously while controlling
for age, education, gender, age at first heroin use, metha-
done dose and days stayed in MMT.
Results
A total of 599 patients who enrolled in an MMT pro-
gram for an average of 184 days signed the consent form
and 46 did not go through the baseline assessment. Of
the 553 of those who completed baseline assessment,
285 and 155 remained in the study each for 6 and 12
months.
Table 2 summarizes the background information and
compares participants who retained in the study for the
6-month follow-up and those who dropped out in 6months after baseline. No difference from chi-square
and t-test analysis was found for gender, age, marital sta-
tus, education, age at first heroin use, HIV, HCV,
whether morphine was tested positive at baseline,
methadone dose at treatment admission, employment,
and number of days enrolled in the MMT before enroll-
ment in this study.
Table 3 lists the WHOQOL-BREF scores at baseline
and at 6-month for participants who completed the
quality-of-life questionnaire at both times. At baseline,
the highest mean score was in the physical domain
(58.53; SD = 15.51) and the lowest mean score was in the
psychological domain (49.89; SD = 16.64). Likewise, at 6
months, the highest mean score was in the physical do-
main (60.13; SD = 14.68) and the lowest was in the psy-
chological domain (53.19; SD = 17.15).
To assess changes in quality of life, the scores at base-
line were subtracted from the scores at 6 months.
Table 2 Comparison of study participants who retained in MMT and those who dropped out of MMT at 6-month follow-up
Retained in MMT at 6-month
follow-up (n = 285)
Dropped out of MMT at 6-month
follow-up (n = 314)
χ2/t p




Age 41.02(9.32) 40.16(9.09) 1.15 0.25




Education (years) 9.22(2.26) (n = 309) 9.1(2.17) 0.29 0.77
Age at first-time heroin intake (n = 283) 27.74(7.36) (n = 218) 26.65(7.34) 1.65 0.10
HIV status (n = 275) (n = 301) 0.01 0.93
Positive 34(12.4) 38(12.6)
Negative 241(87.6) 263(87.4)
HCV Status (n = 264) (n = 287) 1.11 0.58
Positive 248(93.9) 264(92.0)
Negative 16(6.1) 23(8.0)
Morphine status at baseline (n = 247) (n = 266) 2.55 0.28
Positive 69(27.9) 90(33.8)
Negative 178(72.1) 176(66.2)
Methadone dose at treatment intake (mg/day) (SD) (n = 283) 39.19 (20.86) (n = 313) 38.58 (19.90) 0.37 0.72
Days enrolled in MMT before this study (SD) (n = 216) 194.44 (157.86) (n = 282) 175.77 (145.10) 1.37 0.17
Employed (n = 279) (n = 292) 0.44 0.51
Yes 187 (67.0) 188(64.4)
No 92(33.0) 104(35.6)
Note. Variables with missing values were deleted from the analyses. Chi-square and t-test analyses were performed on categorical and continuous variables
respectively to determine if there were differences between dropouts and those who stayed.
Table 3 Quality-of-life (QoL) scores and cost per QoL point
in the four domains at the 6-month assessment (n = 285)






M (SD) M (SD)
Physical 58.53(15.51) 60.13(14.68) 1.6 368.7
Psychological 49.89(16.64) 53.19(17.15) 3.3** 178.7
Social Relations 54.71(18.13) 55.77(17.05) 1.06 556.5
Environmental 52.92(16.97) 55.42(16.20) 2.5** 235.9
Note. Repeated measures analyses of variance of baseline and 6-month follow-
up were performed to control for age, education, gender, age at first heroin
use, methadone dose and days in MMT before study. Cost per QoL point =
Total MMT cost/Incremental QoL gain. MMT cost was $1179.70 in 2009. For
the 6-month calculation, $589.85 (1179.7/2) was used.
*p < .05.**p < .01.
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baseline and 6-month follow-up showed that age, educa-
tion, gender, age at first heroin use, methadone dose and
days in MMT before study were not significantly associ-
ated with changes of quality of life. Table 3 shows that
the greatest mean gain at 6-month follow-up was in the
psychological domain (3.3) and the least in the social do-
main (1.06). Significant improvements were found in the
psychological domain, F(1, 284) = 3.66, p < .01, and the
environmental domain, F(1, 284) = 2.68, p < .01. When
the gained quality of life scores were divided by the total
MMT cost (approximately 1179.7 US dollars) that a pa-
tient had to pay in the year of 2009 (see Table 1), the re-
sults indicated that at 6 months the cost was lowest for
improvement in the psychological domain ($178.70/per
quality-of-life (QoL) unit).
Results from repeated measures analyses of variance of
baseline, 6-month and 12-month follow-ups also showed
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methadone dose and days in MMT before study were
also not significantly associated with changes of quality
of life. Table 3 presents the changes in quality of life and
the cost in dollars of each point increase in the QoL
mean scores between baseline, 6 months, and 12
months. For patients who completed the questionnaire
at all three times (n = 155), the greatest mean increases
in QoL scores were in the psychological domain: base-
line to 6 months (2.84) and baseline to 12 months
(3.95). In the social domain, the corresponding mean in-
creases were 1.27 from baseline to 6 months and 3.02
from baseline to 12-months. The lowest increase (1.58)
was in the physical domain from baseline to 12 months.
Table 4 also shows statistically significant improve-
ments from baseline to 6 months in the psychological
domain, F(1, 154) = 2.35, p < .01, and in the environmen-
tal domain, F(1, 154) = 2.00, p < .01. From baseline to 12
months, there were significant improvements in the psy-
chological domain, F(1, 154) = 3.05, p < .01,and in the so-
cial domain, F(1, 154) = 1.95, p < .01).
The gains in quality of life and cost per QoL point
gained are also presented in Table 4. The results show
that participants had to pay an average of $746.60,
$298.70, $390.60, and $526.70 per year in order to gain
one QoL point in their physical, psychological, social,
and physical domain scores, respectively; note that the
least costly was the psychological domain and the most
costly was the physical domain.
Discussion and conclusions
This study examined long-term self-reported improve-
ment in the quality of life of heroin patients in a MMT
in Taiwan. Employing a longitudinal design, we found
that the MMT improved patients’ quality of life in psy-
chological, social relations, and environmental but not
physical domain, as recorded at 6 and 12 months. Spe-
cifically, patients who stayed in the program for 6
months (n = 285) showed statistically significant im-
provement in their quality of life in the psychological
and environmental domains. Similar positive effects wereTable 4 Quality-of-life (QoL) scores and cost per QoL point in the
Baseline score 6-month 12-month
M(SD) M(SD) M(SD)
Physical 56.80 (15.14) 58.59 (14.48) 58.38 (14.5
Psychological 50.06 (16.23) 52.90 (16.48) 54.01 (17.3
Social Relations 53.49 (18.80) 54.76 (17.23) 56.51 (17.8
Environmental 52.34 (17.04) 54.79 (16.59) 54.58 (16.8
Note. Repeated measures analyses of variance of baseline, 6-month and 12-month f
heroin use, methadone dose and days in MMT before study. Cost per QoL point = T
6-month calculation, $589.85 (1179.7/2) was used.
*p < .05. **p < .01.found in patients who stayed in the program for 12
months (n = 155), indicating that these patients showed
significant improvement in their psychological health
and social relationships.
Overall, our results show that the efficacy of MMT
may exist in improving long-term quality of life varied in
magnitude and as a function of length of time in the
program. Compared with previous studies [21,28], our
results show that the gains in mean quality-of-life scores
were relatively small at both 6 and 12months. The differ-
ences between our study and others in terms of MMT
efficacy may be attributed to methadone dose and differ-
ent sample selection criteria. First, in our study, the
average methadone dose was below 40mg/day which is
much lower than the recommended dose of at least
59mg/day in previous studies [13]. Second, our sample
of patients consisted of drug users who at baseline had
already been participating in their MMT, whereas in the
other studies the baseline assessment was the patients’
first exposure to MMT. De Maeyer et al. [24] noted that
the heroin-dependent persons they studied often found
themselves in a crisis situation at the start of treatment
and entered treatment in very poor condition, resulting
in very poor quality of life at admission. Because it is
likely that the marginal effects of MMT on patients’
quality of life decrease the longer they participate in an
MMT, it would not be surprising if patients who had
never been involved in an MMT program before re-
spond better to MMT than those who had experienced
it before. Therefore, the beneficial effects of MMT on
quality of life in studies such as those of Xiao [18],
Baharom, et al. [28], Maremmani et al. [21], Padaiga
et al. [22], Ponizovsky and Grinshpoon [23], and Wang
et al. [29] are likely to have covered the time period from
patient’s first admission to follow-up treatment. How-
ever, findings on the persistence of MMT effects on
quality of life have been mixed. Some studies found that
patients in treatment for 6 months or longer had a bet-
ter quality of life than at admission [21-23], whereas
Wang et al. [29] and Xiao [18] found that beneficial ef-
fects were observed only during the first to third monthfour domains at the 6- and 12-month assessments (n = 155)
Incremental QoL gain Cost per QoL point
6-month 12-month 6-month 12-month
2) 1.79 1.58 329.5 746.6
7) 2.84* 3.95** 207.7 298.7
5) 1.27 3.02* 464.4 390.6
0) 2.45* 2.24 240.8 526.7
ollow-ups were performed to control for age, education, gender, age at first
otal MMT cost/Incremental QoL gain. MMT cost was $1179.70 in 2009. For the
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patients’ quality of life, but the long-term effects might
not be as significant as the short-term effects identified
by other studies.
In our study, the most significant progress on quality
of life was in the mental health area, with an increase of
3.3 in mean scores after 6 months of treatment and 2.84
after 12, in accord with previous studies [28,30]. For in-
stance, Ha [30] found that MMT had a positive impact
on the quality of life of drug users in Vietnam after 6
months of treatment; the mean was highest for psycho-
logical health (13.28) and lowest for social relationships
(3.94). Baharom et al. [28] found Malaysian patients’
quality of life increased significantly in all four domains,
with the mean score increases ranging from 7.32 in so-
cial relationships to 15.54 in psychological health follow-
ing 6 months of therapy.
By comparing the beneficial effects of MMT 6 months
and 12months after baseline measures, we found that
the improvement in social relationships was significant
only at 12 months. Padaiga et al. [22] found that the
average quality of life of 102 Lithuanian opiate-
dependent individuals significantly improved in all the
domains except social relationships after 6 months of
MMT. One explanation for the lack of effect for social
relationships is that it takes time for heroin users to re-
gain trust from non-drug-using families and relatives.
MMT not only helps in alleviating the physical harm as-
sociated with heroin addiction, but also improves psy-
chological and environmental domains of their lives, as
we found in our study at 6 months. With improvements
in psychological and environmental well-being, patients
would be more willing and able to re-establish social
relationships.
On the other hand, we also found that the physical-
domain scores of patients did not improve significantly
from baseline to 6 months or from 6 to 12 months, al-
though the direction was positive. A possible reason for
this failure is that MMT may reduce heroin users’ crav-
ings for drugs and withdrawal symptoms in as short as
one month, causing them to feel improvement in their
physical status; however, this sense of improvement di-
minishes as MMT continues, such that eventually they
no longer feel any significant progress physically.
Further, in our study the improvements in quality of
life in the four domains were not always significant in
the two post-baseline periods. Significant improvement
in the environmental domain appeared at 6 but not 12
months, which is better than in mental health, where the
scores were nonsignificant for the same groups of pa-
tients at both 6 and 12 months. Another possibility is
that the effectiveness of MMT in improving heroin
users’ quality of life may not be as great in Taiwan as
has been found in other countries. Future studies shouldbe carried out comparing countries at different time pe-
riods to examine the long-term and cross-cultural effects
of MMT on heroin users.
In previous studies, perception of suitable costs and
satisfaction of MMT are predictors of retention [12,25].
In other words, monetary costs and perception of im-
provement in QoL may both be critical factors in deter-
mining how long a patient stays in an MMT program.
In our study, a patient in Taiwan has to pay $1,179.70
per year to participate in MMT based on regulations of
Taiwan Department of Health. This cost from a patient’s
perspective is surprisingly high, which result in the high
cost per QoL increment in four domains.
In addition to the benefits in personal well-being un-
covered in our study and others, MMT might also pro-
vide additional benefits. First, improvements in the four
domains might increase the patient’s chances of
obtaining or retaining a job. Second, family problems
such as domestic violence or child abuse should be less
likely to occur following the improvement in the pa-
tient’s quality of life. Finally, once the patient becomes
less drug-dependent, the likelihood of involvement in
drug-related crimes should be lower, a benefit to the so-
ciety as a whole. Given that the direct and indirect eco-
nomic costs associated with drug abuse are tremendous
(more than $193 billion in the U.S. in 2007; see U.S. De-
partment of Justice, 2011), and that MMT has been
shown to be effective in reducing patients’ drug depend-
ence, it follows that MMT should be considered a viable
way to control and prevent the adverse consequences as-
sociated with drug abuse. Further, the costs of MMT are
small compared with the social costs of criminal activity,
loss of productive employment, and subsequent health
care utilization on the part of active drug users. To re-
duce these drug-related economic losses, public policy
makers should consider either completely subsidizing
MMT or regulating it as a treatment for compulsive
drug users.
This study employed a single-group prospective design
which has methodological limitations in terms of causal
inferences. First, we did not compare heroin users with a
control group not in the MMT. The efficacy of MMT
observed in this study may need to take threats of in-
ternal validity into consideration and, namely, the posi-
tive outcomes may be caused by other factors such as
maturation, testing, and sample selection bias. Second,
participant attrition has been shown to limit the
generalizability of a study’s findings. Despite the large at-
trition rate in our study, no significant differences in
demographics or clinical characteristics were found be-
tween individuals who completed at least 6 months of
the study and those who dropped out before that. This
outcome suggests that our findings are still valid. Third,
the data were gathered through patient self-reports,
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may adopt alternative assessment strategies to maximize
the disclosure of sensitive information; for example,
ACASI – audio computer-assisted self-interview may be
used to collect sensitive information. However, it is be-
coming increasingly important in the treatment of
chronic diseases to use subjective quality of life mea-
sures as an outcome index.
Another limitation of our study is that the MMT costs
listed in the Table 1 do not include all the direct and in-
direct costs. Note that this omission does not mean that
every heroin user received all the treatments or exami-
nations. In fact, whether such clinical examinations are
performed depends on the psychiatrist’s professional de-
cision regarding the appropriate methadone dosage.
Moreover, we did not calculate opportunity costs such
as the productivity loss from participating in an MMT
program and the cost of police time spent dealing with
crimes. We assumed that taking methadone everyday
might have effects on a heroin user’s job performance,
but the effects turned out to be rather negligible. Also,
the costs for the time spent by police dealing with crime
were difficult to estimate. Nevertheless, future studies
are warranted to calculate the costs that are both dir-
ectly and indirectly associated with MMT.
The results of the present study have important clin-
ical implications for treating and retaining patients in
MMT, particularly with respect to quality of life. Current
clinical practice of MMT rarely implements the treat-
ment and assessment of life of quality. Thus, we
propose: 1) in addition to reduction in opioid drug use
and HIV risk behavior, improvement in long-term qual-
ity of life can be of importance as an indicator of treat-
ment outcome measure; 2) to carefully re-evaluate
methadone maintenance dose prescribed in Taiwan. Pre-
vious study showed that higher methadone dose and
longer duration of treatment were associated with better
quality of life in MMT patients [29]. Higher methadone
dose may reduce the severity of craving and relapse and
retain in MMT longer [13]. Our findings showed that
the average methadone dose prescribed in this Taiwan
sample is lower than the recommended level. The re-
evaluation and to prescribe appropriate methadone dose
in Taiwan may be necessary in order to gain better qual-
ity of life for MMT patients; 3) to treat the comorbidity
of other psychiatric disorders and infectious diseases, i.e.
depression, anxiety disorder, and HIV/HCV is important
to improve quality of life. Psychiatric comorbidity was as
high as 78% in MMT patients [31]. Quality of life was
worse in the patients of heroin dependence comorbidity
of other psychiatric disorders [31] and among individ-
uals with HIV [32]; 4) to establish a comprehensive
psycho-social intervention in addition to medication to
improve daily social function. Our results indicate theimportance of longer duration in MMT with improve-
ment of social relationship for patients. Compared to
physiological and psychological well-being, increase in
quality of social relations may need more time to show
the effect. We suggest that social well-being can be one
of the long-term clinical outcome measures.
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